NEUVOGEN is advancing a broad pipeline of therapeutic whole cell cancer vaccine candidates designed to activate the patient’s immune system to target and eliminate existing tumors and prevent future metastases.
Our research programs focus on therapeutic cancer vaccines to treat a wide range of tumor types across numerous solid tumor indications.
Unprecedented Immune Breadth
Our proprietary activation technology drives T cell responses against a wide and diverse set of tumor antigens — far beyond the narrow targets of traditional vaccines. This breadth is designed to target the primary tumor, micro-metastases, and metastases by activating the patient’s own immune system.
Built for Real-World Use
NEUVOGEN vaccines are off-the-shelf, intradermally administered, and ready to be used in any clinical setting — no patient-specific customization needed. They’re simple to deliver, scalable to manufacture, and easier to incorporate into the standard of care.
Broader Access for Patients
Because of our efficient manufacturing and simplified logistics, our vaccines are designed to dramatically lower the cost of goods, expanding access to patients who might otherwise be left behind.